Y Intercept Hong Kong Ltd Acquires New Shares in Seer, Inc. (NASDAQ:SEER)

Y Intercept Hong Kong Ltd acquired a new stake in Seer, Inc. (NASDAQ:SEER) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 15,412 shares of the company’s stock, valued at approximately $36,000.

Several other hedge funds have also recently bought and sold shares of SEER. Barclays PLC increased its position in Seer by 34.1% during the third quarter. Barclays PLC now owns 64,426 shares of the company’s stock worth $127,000 after buying an additional 16,382 shares in the last quarter. Geode Capital Management LLC increased its position in Seer by 5.9% during the third quarter. Geode Capital Management LLC now owns 446,329 shares of the company’s stock worth $879,000 after buying an additional 25,002 shares in the last quarter. Quadrature Capital Ltd increased its position in Seer by 301.7% during the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock worth $112,000 after buying an additional 42,875 shares in the last quarter. XTX Topco Ltd purchased a new position in Seer during the third quarter worth $123,000. Finally, JPMorgan Chase & Co. increased its position in Seer by 67.5% during the third quarter. JPMorgan Chase & Co. now owns 175,354 shares of the company’s stock worth $345,000 after buying an additional 70,671 shares in the last quarter. 75.20% of the stock is owned by hedge funds and other institutional investors.

Seer Stock Performance

Seer stock opened at $2.04 on Thursday. The stock has a fifty day moving average of $2.30 and a two-hundred day moving average of $2.12. The company has a market capitalization of $120.29 million, a price-to-earnings ratio of -1.57 and a beta of 1.58. Seer, Inc. has a fifty-two week low of $1.56 and a fifty-two week high of $2.63.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.